- Co-Founder and Director Greg
Gubitz appointed Chair of the Board of HLS
TORONTO, May 24, 2022
/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS),
a pharmaceutical company focusing on central nervous system and
cardiovascular markets, announces that Bill
Wells, Executive Chair of the Board, has retired from the
board and his executive duties at HLS effective May 23, 2022. Mr. Wells intends to focus on other
business interests and has agreed to work with the Company to
facilitate an orderly transition. Greg
Gubitz has been appointed Chair of the Board effective
immediately.
Mr. Wells co-founded HLS in 2014 and has served since inception
as Executive Chair as well as President and Chair of HLS's
Barbados subsidiary. Before
that he was involved in three successful turnaround efforts of
major public companies and led the turnaround of Biovail, first as
Lead Director of the board of directors and then as Chief Executive
Officer.
"On behalf of our Board and HLS's management team, we thank Bill
for his service and longstanding commitment to the Company," stated
Gilbert Godin, HLS's Chief Executive
Officer. "We greatly appreciate the leadership, insight, and
expertise that Bill has provided over the past eight years helping
to position HLS for its exciting future growth."
Mr. Wells stated, "I look back on co-founding HLS with great
pride and I am honored to have worked with HLS co-founders
Greg Gubitz, Gilbert Godin, Joe
Maclean and the Board from the very beginning as Executive
Chair. HLS has a bright future as a dynamic North American
pharmaceutical company with an enviable product portfolio. I also
want to thank my fellow directors for our many collaborations, and
I wish HLS great success."
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a
pharmaceutical company focused on the acquisition and
commercialization of late-stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products targeting the
central nervous system and cardiovascular therapeutic areas. HLS's
management team is composed of seasoned pharmaceutical executives
with a strong track record of success in these therapeutic areas
and at managing products in each of these lifecycle stages. For
more information visit: www.hlstherapeutics.com
FORWARD LOOKING INFORMATION
This release includes
forward-looking statements regarding HLS and its business. Such
statements are based on the current expectations and views of
future events of HLS's management. In some cases the
forward-looking statements can be identified by words or phrases
such as "may", "will", "expect", "plan", "anticipate", "intend",
"potential", "estimate", "believe" or the negative of these terms,
or other similar expressions intended to identify forward-looking
statements, including, among others, statements with respect to
HLS's pursuit of additional product and pipeline opportunities in
certain therapeutic markets, statements regarding growth
opportunities, expectations regarding financial performance, and
the NCIB and ASPP. The forward-looking events and circumstances
discussed in this release may not occur and could differ materially
as a result of known and unknown risk factors and uncertainties
affecting HLS, including risks relating to the specialty
pharmaceutical industry, risks related to the regulatory approval
process, economic factors and many other factors beyond the control
of HLS. Forward-looking statements and information by their nature
are based on assumptions and involve known and unknown risks,
uncertainties and other factors which may cause HLS's actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statement
or information. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. A
discussion of the material risks and assumptions associated with
this release can be found in the Company's Annual Information Form
dated March 16, 2022, and
Management's Discussion and Analysis dated May 4, 2022, both of which have been filed on
SEDAR and can be accessed at www.sedar.com. Accordingly, readers
should not place undue reliance on any forward-looking statements
or information. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made and HLS undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
SOURCE HLS Therapeutics Inc.